share_log

Stifel Maintains Buy on Verve Therapeutics, Lowers Price Target to $40

Moomoo 24/7 ·  Apr 3 08:47

Stifel analyst Dae Gon Ha maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment